9-hexylaminoacridine | 74054-23-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9-hexylaminoacridine
• 英文别名: 9-Acridinamine, N-hexyl-；N-hexylacridin-9-amine
• CAS: 74054-23-2
• 化学式: C₁₉H₂₂N₂
• 分子量: 278.397
• InChiKey: PVGNKKWEHUZWDD-UHFFFAOYSA-N

物化性质

• 熔点：
  116 °C
• 沸点：
  450.7±20.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-苯基邻氨基苯甲酸 在 三氯氧磷 作用下， 以 苯酚 为溶剂， 反应 1.0h， 生成 9-hexylaminoacridine
  参考文献：
  名称：

  Synthesis and evaluation of N-alkyl-9-aminoacridines with antibacterial activity

  摘要：

  A series of 9-alkylaminoacridines were synthesized and evaluated for activity against two strains of methicillin-resistant and one strain of methicillin-sensitive Staphylococcus aureus. Results are presented that show a clear structure activity relationship between the N-alkyl chain length and antibacterial activity with peak MIC99 values of 2-3 mu M for alkyl chains ranging from 10 to 14 carbons in length. Although prior work has linked the function of acridine-based compounds to intercalation and topoisomerase inhibition, the present results show that 9-alkylaminoacridines likely function as amphiphilic membrane-active disruptors potentially in a similar manner as quaternary ammonium antimicrobials. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.037

文献信息

• Compositions for in-situ active compound assembly
  申请人：SCRIPPS CLINIC AND RESEARCH FOUNDATION

  公开号：EP0603160A2

  公开（公告）日：1994-06-22

  A composition for chemically treating a target condition, existing at a microenvironment localized within an environment, with an active compound, the composition comprising precursor components which can conjugate covalently to form the active compound in situ, and for which the covalent conjugation is more favourable at the microenvironment of the target condition than in the surrounding environment. Disclosed examples include biologically-active compounds which are preferentially formed in the microenvironment of tumour cells.

  一种用于用活性化合物化学治疗存在于环境局部微环境中的目标病症的组合物，该组合物包含可共价结合以在原位形成活性化合物的前体成分，对于这些前体成分，共价结合在目标病症的微环境中比在周围环境中更有利。已公开的例子包括在肿瘤细胞的微环境中优先形成的生物活性化合物。
• Galy, Jean Pierre; Elguero, Jose; Vincent, Emile Jean, Heterocycles, 1980, vol. 14, # 3, p. 311 - 313
  作者：Galy, Jean Pierre、Elguero, Jose、Vincent, Emile Jean

  DOI：——

  日期：——
• $i(IN SITU) ACTIVE COMPOUND ASSEMBLY
  申请人：SCRIPPS CLINIC AND RESEARCH FOUNDATION

  公开号：EP0312543A1

  公开（公告）日：1989-04-26
• EP0312543A4
  申请人：——

  公开号：EP0312543A4

  公开（公告）日：1990-12-27
• [EN] IN SITU ACTIVE COMPOUND ASSEMBLY
  申请人：SCRIPPS CLINIC AND RESEARCH FOUNDATION

  公开号：WO1988000047A1

  公开（公告）日：1988-01-14

  (EN) Differences in microenvironments associated with various cells and other conditions in this environment are used to advantage in effecting the $i(in situ) construction of biologically active agents at target locations in preference to surroundings which are desired to be unaffected.(FR) On utilise avec avantage les différences entre les micro-environnements associés à des cellules diverses et à d'autres conditions de ces environnements afin d'obtenir la construction $i(in situ) d'agents biologiquement actifs à des emplacements cibles plutôt que dans une zone environnante que l'on ne souhaite pas affecter.